Status:
COMPLETED
Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-100 years
Brief Summary
Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.
Detailed Description
The survey- based study was conducting amongst HCPs and patients/caregivers in selected European countries including Germany, Netherlands, Nordics (Denmark, Sweden), Spain and Croatia, plus Canada, to...
Eligibility Criteria
Inclusion
- Physicians were considered eligible for the survey if they meet the following screening criteria:
- Care for relapsing MS (RMS) patients
- Personally prescribed disease modifying therapies to MS patients, and;
- Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.
- Nurses were considered eligible for the survey if they:
- Provide supportive care for RMS patients
- Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.
- Patient inclusion criteria include:
- \- Had initiated onto Mayzent (siponimod) to treat their MS since reimbursement
Exclusion
- \-
Key Trial Info
Start Date :
December 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 16 2025
Estimated Enrollment :
335 Patients enrolled
Trial Details
Trial ID
NCT05301907
Start Date
December 2 2021
End Date
May 16 2025
Last Update
December 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Basel, Switzerland